Sep 15, 2023
Beginning September 16th, Walgreens, a pharmacy and retail leader who plays a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for the nation’s medically...Topics: Advocacy/ Awareness/ Community Partners/ COVID-19/ Living with Sarcoidosis/ News
Jul 13, 2023
The Foundation for Sarcoidosis Research (FSR) is pleased to announce the appointment of Calvin Harris Jr., CPA and Joel D. Rosen, Esq. to the FSR Board of Directors. “We are thrilled to welcome Calvin and Joel to the FSR Board of Directors,” said Dr....Topics: Community Partners/ News/ Other
Apr 26, 2023
Recently, we asked our dedicated and generous Sarcoidosis Awareness Campaign Gold Level Sponsor, aTyr Pharma, Inc., to share more about their passion for raising awareness and improving the lives of those impacted by sarcoidosis. Check out how they are accelerating...Topics: Awareness/ Community Partners/ Research
Jul 18, 2022
On April 21, 2022, The Foundation for Sarcoidosis Research (FSR) hosted a virtual Patient Listening Session on Pulmonary Sarcoidosis with the US Food and Drug Administration (FDA). FDA Patient Listening Sessions are small, informal, non-regulatory, non-public...Topics: Advocacy/ Community Partners/ News/ Other/ Patient Voices
Nov 3, 2021
We are proud to announce that they have been selected as an awardee for the Chan Zuckerberg Initiative (CZI) Rare As One Cycle 2 grant which will provide $600,000 to improve diagnostics and increase research in sarcoidosis. This work is part of CZI’s Rare...Topics: Advocacy/ Community Partners/ News
Sep 15, 2021
My journey with Interstitial Lung Disease (ILD) started about 15 years ago, although I did not know it at the time, nor did the physicians who were then treating me. At an annual physical, at the age of 46, I mentioned that my knees were a bit sore after physical...Topics: Advocacy/ Community Partners/ Living with Sarcoidosis/ Patient Voices
Dec 17, 2020
Xentria Inc. has recently announced they received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for their intravenous TNF-inhibitor, XTMAB-16. The FDA grants orphan status to drugs being developed to treat those with rare diseases. This...Topics: Community Partners/ Research
Oct 29, 2020
The following is an exciting announcement from an FSR partner, Boehringer Ingelheim – see the release on their website here. Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19...Topics: Community Partners/ News
Apr 16, 2020
FSR is a proud member of NORD, the National Organization for Rare Disorders. On April 15th, NORD announced the creation of a program to provide financial assistance for members of the rare disease community who have been impacted by COVID-19. Read the release below or...Topics: Community Partners/ News
Apr 4, 2020
Help FSR support our partners in the healthcare system during COVID-19Like many healthcare systems across the country and world right now, FSR’s friends at National Jewish Health in Colorado are experiencing a shortage of Personal Protective Equipment, or PPEs....Topics: Community Partners
